ARHGEF3 Activators
ARHGEF3 activators comprise a set of chemical entities that specifically enhance the guanine nucleotide exchange factor (GEF) activity of ARHGEF3 through various intracellular signaling cascades. Forskolin, by escalating the concentration of cAMP within the cell, indirectly facilitates ARHGEF3's GEF functionality through the activation of protein kinase A (PKA). PKA catalyzes the phosphorylation of proteins that interact with ARHGEF3, amplifying its capacity to activate Rho GTPases, thereby influencing cell morphology and motility. Phorbol 12-myristate 13-acetate (PMA) operates through a parallel mechanism, utilizing protein kinase C (PKC) to phosphorylate and regulate proteins that control ARHGEF3 activity. This modulation by PMA promotes ARHGEF3's role in the activation of Rho GTPases, integral to cytoskeletal reorganization.
Once a subset of compounds is confirmed as potential ALG-3 activators, the next step involves an in-depth analysis of their interaction with ALG-3. Techniques such as X-ray crystallography or NMR spectroscopy may be utilized to reveal the exact mode of interaction between the activator and ALG-3, providing a three-dimensional view of the binding site and the molecular changes that occur upon activation. Additionally, biophysical methods like surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) can yield important information regarding the kinetics and affinity of the interaction between ALG-3 and the activators. These data are crucial for understanding the efficiency and specificity with which these compounds enhance ALG-3's activity. Structure-activity relationship (SAR) studies are also a key component of the development process. By systematically altering the chemical structure of the activators and evaluating the resultant effects on ALG-3 activation, researchers can identify the crucial chemical groups necessary for activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a diacylglycerol (DAG) analog that activates protein kinase C (PKC). PKC activation can enhance ARHGEF3 activity by phosphorylating substrates that modulate the GEF activity of ARHGEF3, leading to increased activation of Rho GTPases. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
8-Br-cAMP is a cell-permeable cAMP analog that activates PKA. PKA can then phosphorylate regulatory proteins that interact with ARHGEF3, enhancing its GEF activity towards Rho GTPases. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels. Elevated calcium can activate calmodulin-dependent kinase (CaMK), which in turn can enhance ARHGEF3 activity by modulating its interaction with Rho GTPases. | ||||||
MIRA-1 | 72835-26-8 | sc-204087 sc-204087A | 10 mg 50 mg | $118.00 $452.00 | 1 | |
GTPγS is a non-hydrolyzable GTP analog that can bind and stabilize the active form of Rho GTPases. The stabilization of active Rho GTPases can lead to the indirect enhancement of ARHGEF3's GEF activity by facilitating positive feedback loops. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P binds to its G protein-coupled receptors, which can activate ARHGEF3 through downstream signaling pathways involving Rho GTPases, enhancing ARHGEF3-mediated cytoskeletal reorganization. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a tyrosine kinase inhibitor that can reduce competitive signaling pathways, potentially allowing ARHGEF3 to more effectively facilitate the activation of Rho GTPases, thereby enhancing its GEF activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor that can reduce the downstream signaling of Rho GTPases. The inhibition of ROCK leads to reduced negative feedback on ARHGEF3, thus potentially enhancing ARHGEF3's ability to activate Rho GTPases. | ||||||
Cilostazol | 73963-72-1 | sc-201182 sc-201182A | 10 mg 50 mg | $109.00 $322.00 | 3 | |
Cilostazol inhibits phosphodiesterase type 3 (PDE3) leading to increased cAMP levels. The resultant activation of PKA can enhance ARHGEF3 activity through cAMP-dependent phosphorylation of proteins that interact with ARHGEF3. | ||||||